Comment
0
Tweet
0
Print
RSS Feeds

FDA Approves ImmunoGen/Roche Breast Cancer Drug

Saturday - 2/23/2013, 4:35am  ET

The Food and Drug Administration has approved a new type of breast cancer drug developed by ImmunoGen and Roche (NASDAQOTH: RHHBY), and will be marketed by the latter. The medication, known by the brand name Kadcyla, is used to treat HER 2-positive metastatic breast cancer. It is a combination of Herceptin, an existing Roche drug, with a pair of components developed by ImmunoGen.

HER2 is a protein found on the tumors of roughly 20% to 25% of patients with breast cancer.

The approval will trigger a $10.5 million payment from Roche to ImmunoGen. The latter will also be paid royalties of up to 5% on sales of Kadcyla, which will cost $9,800 per month.

This article was originally published as FDA Approves ImmunoGen/Roche Breast Cancer Drugon Fool.com

Copyright © 2009 The Motley Fool, LLC. All rights reserved.